Advertisement

Naunyn-Schmiedeberg's Archives of Pharmacology

, Volume 392, Issue 9, pp 1141–1149 | Cite as

Berberine ameliorates diabetic neuropathic pain in a rat model: involvement of oxidative stress, inflammation, and μ-opioid receptors

  • Jun Dong
  • Zhongfu Zuo
  • Wei Yan
  • Wenqiang Liu
  • Qingyu Zheng
  • Xuezheng LiuEmail author
Original Article
  • 140 Downloads

Abstract

Berberine, a chemical found in plants, is used as a supplement for diabetes. This study aimed to investigate the effects and the underlying molecular regulations of berberine in diabetic neuropathic pain in a rat model of diabetes. Rats were injected with streptozotocin (STZ) to induce diabetes and then were treated with berberine. Blood glucose levels and body weight were measured. Thermal and mechanical nociception were assessed by paw pressure test and hot tail immersion test. Oxidative stress was assessed by lipid peroxidation, production of reactive oxygen species (ROS) and catalase activity. Neuroinflammation was assessed by tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) protein levels. Finally, μ-opioid receptor (MOR) protein and mRNA levels were measured. We found that berberine treatment partially suppressed blood glucose levels and restored body weight in diabetic rats. Berberine also suppressed STZ-induced oversensitivity of mechanical and thermal nociception. Additionally, berberine partially suppressed oxidative stress and inflammation of diabetic rats. Finally, berberine significantly enhanced protein and mRNA expression levels of μ-opioid receptor (MOR). Our findings suggest that berberine is a potential therapeutic alleviating diabetes and diabetic neuropathic pain, probably through suppression of oxidative stress and neuroinflammation that may be mediated by MOR.

Keywords

Berberine Diabetic neuropathic pain Oxidative stress Inflammation μ-Opioid receptor 

Notes

Author contribution statement

Jun Dong and Zhongfu Zuo contributed equally to this work. Jun Dong, Zhongfu Zuo, Wei Yan, and Wenqiang Liu conceived and designed research. Wenqiang Liu, and Qingyu Zheng analyzed data. Jun Dong and Xuezheng Liu wrote the manuscript. All authors read and approved the manuscript.

Funding information

The study was supported by the National Natural Science Foundation of China (81571383); China Postdoctoral Science Foundation (2017 M612870); and Program for Liaoning Excellent Talents in University (LJQ2015069).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. Albers JW, Pop-Busui R (2014) Diabetic neuropathy: mechanisms, emerging treatments, and subtypes. Curr Neurol Neurosci Rep 14:473CrossRefGoogle Scholar
  2. Anselmi L, Huynh J, Duraffourd C, Jaramillo I, Vegezzi G, Saccani F, Boschetti E, Brecha NC, De Giorgio R, Sternini C (2015) Activation of mu opioid receptors modulates inflammation in acute experimental colitis. Neurogastroenterol Motil 27:509–523CrossRefGoogle Scholar
  3. Biessels GJ, Bril V, Calcutt NA, Cameron NE, Cotter MA, Dobrowsky R, Feldman EL, Fernyhough P, Jakobsen J, Malik RA, Mizisin AP, Oates PJ, Obrosova IG, Pop-Busui R, Russell JW, Sima AA, Stevens MJ, Schmidt RE, Tesfaye S, Veves A, Vinik AI, Wright DE, Yagihashi S, Yorek MA, Ziegler D, Zochodne DW (2014) Phenotyping animal models of diabetic neuropathy: a consensus statement of the diabetic neuropathy study group of the EASD (Neurodiab). J Peripher Nerv Syst 19:77–87CrossRefGoogle Scholar
  4. Caliceti C, Franco P, Spinozzi S, Roda A, Cicero AF (2016) Berberine: new insights from pharmacological aspects to clinical evidences in the management of metabolic disorders. Curr Med Chem 23:1460–1476CrossRefGoogle Scholar
  5. Chang W, Chen L, Hatch GM (2015) Berberine as a therapy for type 2 diabetes and its complications: from mechanism of action to clinical studies. Biochem Cell Biol 93:479–486CrossRefGoogle Scholar
  6. Chen C, Lu M, Pan Q, Fichna J, Zheng L, Wang K, Yu Z, Li Y, Li K, Song A, Liu Z, Song Z, Kreis M (2015) Berberine improves intestinal motility and visceral pain in the mouse models mimicking diarrhea-predominant irritable bowel syndrome (IBS-D) symptoms in an opioid-receptor dependent manner. PLoS One 10:e0145556CrossRefGoogle Scholar
  7. Coskun O, Kanter M, Korkmaz A, Oter S (2005) Quercetin, a flavonoid antioxidant, prevents and protects streptozotocin-induced oxidative stress and beta-cell damage in rat pancreas. Pharmacol Res 51:117–123CrossRefGoogle Scholar
  8. Javed S, Alam U, Malik RA (2015) Burning through the pain: treatments for diabetic neuropathy. Diabetes Obes Metab 17:1115–1125CrossRefGoogle Scholar
  9. Karlsson HK, Tuominen L, Tuulari JJ, Hirvonen J, Parkkola R, Helin S, Salminen P, Nuutila P, Nummenmaa L (2015) Obesity is associated with decreased mu-opioid but unaltered dopamine D2 receptor availability in the brain. J Neurosci 35:3959–3965CrossRefGoogle Scholar
  10. Kiasalari Z, Rahmani T, Mahmoudi N, Baluchnejadmojarad T, Roghani M (2017) Diosgenin ameliorates development of neuropathic pain in diabetic rats: involvement of oxidative stress and inflammation. Biomed Pharmacother 86:654–661CrossRefGoogle Scholar
  11. Kou ZZ, Wan FP, Bai Y, Li CY, Hu JC, Zhang GT, Zhang T, Chen T, Wang YY, Li H, Li YQ (2016) Decreased endomorphin-2 and mu-opioid receptor in the spinal cord are associated with painful diabetic neuropathy. Front Mol Neurosci 9:80CrossRefGoogle Scholar
  12. Li Z, Geng YN, Jiang JD, Kong WJ (2014) Antioxidant and anti-inflammatory activities of berberine in the treatment of diabetes mellitus. Evid Based Complement Alternat Med 2014:289264Google Scholar
  13. Low PA, Nickander KK, Tritschler HJ (1997) The roles of oxidative stress and antioxidant treatment in experimental diabetic neuropathy. Diabetes 46(Suppl 2):S38–S42CrossRefGoogle Scholar
  14. Maffi P, Secchi A (2017) The burden of diabetes: emerging data. Dev Ophthalmol 60:1–5CrossRefGoogle Scholar
  15. Mao Y, Li Z, Chen K, Yu H, Zhang S, Jiang M, Ma Y, Liang C, Liu H, Li H, Hua Q, Zhou H, Sun Y, Fan X (2017) Antinociceptive effect of ghrelin in a rat model of irritable bowel syndrome involves TRPV1/opioid systems. Cell Physiol Biochem 43:518–530CrossRefGoogle Scholar
  16. Nathan DM (2015) Diabetes: advances in diagnosis and treatment. JAMA 314:1052–1062CrossRefGoogle Scholar
  17. O’Brien PD, Sakowski SA, Feldman EL (2014) Mouse models of diabetic neuropathy. ILAR J 54:259–272CrossRefGoogle Scholar
  18. Ola MS, Aleisa AM, Al-Rejaie SS, Abuohashish HM, Parmar MY, Alhomida AS, Ahmed MM (2014) Flavonoid, morin inhibits oxidative stress, inflammation and enhances neurotrophic support in the brain of streptozotocin-induced diabetic rats. Neurol Sci 35:1003–1008CrossRefGoogle Scholar
  19. Paisley P, Serpell M (2017) Improving pain control in diabetic neuropathy. Practitioner 261:23–26Google Scholar
  20. Schiene K, Tzschentke TM, Schroder W, Christoph T (2015) Mechanical hyperalgesia in rats with diabetic polyneuropathy is selectively inhibited by local peripheral nociceptin/orphanin FQ receptor and micro-opioid receptor agonism. Eur J Pharmacol 754:61–65CrossRefGoogle Scholar
  21. Toth C (2014) Diabetes and neurodegeneration in the brain. Handb Clin Neurol 126:489–511CrossRefGoogle Scholar
  22. Valsecchi AE, Franchi S, Panerai AE, Rossi A, Sacerdote P, Colleoni M (2011) The soy isoflavone genistein reverses oxidative and inflammatory state, neuropathic pain, neurotrophic and vasculature deficits in diabetes mouse model. Eur J Pharmacol 650:694–702CrossRefGoogle Scholar
  23. van Beek M, Geurts JW, Slangen R, Schaper NC, Faber CG, Joosten EA, Dirksen CD, van Dongen RT, van Kuijk SMJ, van Kleef M (2018) Severity of neuropathy is associated with long-term spinal cord stimulation outcome in painful diabetic peripheral neuropathy: five-year follow-up of a prospective two-center clinical trial. Diabetes Care 41:32–38CrossRefGoogle Scholar
  24. Wan FP, Bai Y, Kou ZZ, Zhang T, Li H, Wang YY, Li YQ (2016) Endomorphin-2 inhibition of substance P signaling within Lamina I of the spinal cord is impaired in diabetic neuropathic pain rats. Front Mol Neurosci 9:167Google Scholar
  25. Wong TY, Cheung CM, Larsen M, Sharma S, Simo R (2016) Diabetic retinopathy. Nat Rev Dis Primers 2:16012CrossRefGoogle Scholar
  26. Yang S, Yu Z, Sun W, Jiang C, Ba X, Zhou Q, Xiong D, Xiao L, Deng Q, Hao Y (2018) The antiviral alkaloid berberine ameliorates neuropathic pain in rats with peripheral nerve injury. Acta Neurol Belg.  https://doi.org/10.1007/s13760-018-1006-9
  27. Zan Y, Kuai CX, Qiu ZX, Huang F (2017) Berberine ameliorates diabetic neuropathy: TRPV1 modulation by PKC pathway. Am J Chin Med 45:1709–1723CrossRefGoogle Scholar
  28. Zhao X, Li XL, Liu X, Wang C, Zhou DS, Ma Q, Zhou WH, Hu ZY (2015) Antinociceptive effects of fisetin against diabetic neuropathic pain in mice: engagement of antioxidant mechanisms and spinal GABAA receptors. Pharmacol Res 102:286–297CrossRefGoogle Scholar
  29. Zhou J, Du X, Long M, Zhang Z, Zhou S, Zhou J, Qian G (2016) Neuroprotective effect of berberine is mediated by MAPK signaling pathway in experimental diabetic neuropathy in rats. Eur J Pharmacol 774:87–94CrossRefGoogle Scholar
  30. Zhu L, Han J, Yuan R, Xue L, Pang W (2018) Berberine ameliorates diabetic nephropathy by inhibiting TLR4/NF-kappaB pathway. Biol Res 51:9CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Jun Dong
    • 1
    • 2
  • Zhongfu Zuo
    • 3
    • 4
  • Wei Yan
    • 2
  • Wenqiang Liu
    • 3
  • Qingyu Zheng
    • 3
  • Xuezheng Liu
    • 1
    • 3
    Email author
  1. 1.Department of Anatomy, Histology and Embryology, School of Basic Medical SciencesGuangxi Medical UniversityNanningChina
  2. 2.Department of Anatomy, Histology and EmbryologyJinzhou Medical UniversityJinzhouChina
  3. 3.Liaoning Key Laboratory of Diabetic Cognitive and Perceptive Dysfunction, Department of Anatomy, Histology and EmbryologyJinzhou Medical UniversityJinzhouChina
  4. 4.Department of Anatomy, Histology and Embryology, Postdoctoral Research StationGuangxi Medical UniversityNanningChina

Personalised recommendations